| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 88.197 | 126.565 | 152.726 | 151.959 | 137.629 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 93.081 | 136.616 | 170.002 | 153.753 | 146.296 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 91.211 | 131.644 | 158.700 | 141.856 | 153.282 | 6.166 | 5.843 | 5.897 | 715 | 386 |
| Gross Profit/Loss - EUR | 1.870 | 4.971 | 11.302 | 11.897 | -6.986 | -6.166 | -5.843 | -5.897 | -715 | -386 |
| Net Profit/Loss - EUR | 1.571 | 4.190 | 9.494 | 10.360 | -6.986 | -6.166 | -5.843 | -5.897 | -715 | -386 |
| Employees | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Krilum Parafarmaceutics Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 10.902 | 35.206 | 28.517 | 22.083 | 15.830 | 0 | 0 | 0 |
| Current Assets | 9.728 | 18.439 | 14.615 | 14.171 | 5.840 | 3.447 | 3.291 | 3.185 | 2.460 | 2.061 |
| Inventories | 0 | 0 | 52 | 0 | 1.217 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 4.236 | 4.502 | 1.418 | 10.456 | 4.609 | 536 | 540 | 564 | 698 | 767 |
| Cash | 5.491 | 13.937 | 13.145 | 3.715 | 14 | 2.911 | 2.751 | 2.622 | 1.762 | 1.294 |
| Shareholders Funds | 5.911 | 10.041 | 30.266 | 40.070 | 32.308 | 25.530 | 19.121 | 3.185 | 2.460 | 2.061 |
| Social Capital | 45 | 45 | 10.945 | 10.745 | 10.537 | 10.337 | 10.108 | 10.139 | 10.108 | 10.052 |
| Debts | 5.740 | 10.303 | 1.314 | 14.030 | 2.049 | 0 | 0 | 0 | 0 | 0 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4619 - 4619" | |||||||||
| CAEN Financial Year |
4619
|
|||||||||
Comments - Krilum Parafarmaceutics Srl